Tag - CVKD

Executive Moves

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the appointment of Lee Scott Golden, MD, to its board of directors (BOD) as an independent director, effective immediately. Dr. Golden currently serves as EVP and CMO...

December 1, 2025

Developments

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Cadrenal Therapeutics (NASDAQ: CVKD) has announced clinical trial initiation plans for its lead late-stage candidate, tecarfarin, for the treatment of patients with end-stage kidney disease (ESKD) transitioning to...

August 5, 2025

Tag - CVKD

Cadrenal appoints Dr. Lee Golden to BOD

Cadrenal reveals clinical trial plans for tecarfarin in ESKD

Subscribe